Impella支持与药物治疗在院外心脏骤停后心源性休克中的比较
该回顾性单中心研究纳入2014年9月至2016年9月因AMI导致院外心脏骤停后心源性休克的90例连续患者,其中27例接受Impella支持、63例仅接受药物治疗。Impella组低流量时间更长(29.54±10.21 vs 17.57±8.3 min,p<0.001)、入院乳酸更高(4.75 [IQR 3.8-11] vs 3.6 [IQR 2.6-3.9] mmol/L,p=0.03)、基线左室射血分数更低(25% [IQR 25-35] vs 45% [IQR 35-51.25],p<0.001)。经倾向评分匹配后,Impella组出院生存率显著更高(65% vs 20%,p=0.01),6个月生存率也更高(60% vs 20%,p=0.02)。作者认为Impella支持与更好的出院和6个月生存相关。
要点
- 倾向评分匹配后,Impella组出院生存率65% vs 药物治疗组20%(p=0.01),6个月生存率60% vs 20%(p=0.02)。
- Impella组基线病情更重:低流量时间29.54±10.21 vs 17.57±8.3 min(p<0.001),入院乳酸4.75 vs 3.6 mmol/L(p=0.03),LVEF 25% vs 45%(p<0.001)。
- 研究为回顾性单中心设计,纳入2014年9月至2016年9月共90例AMI合并院外心脏骤停后心源性休克患者。
- 作者结论为Impella支持与更好的出院及6个月生存相关,属关联性发现。
适用人群与场景
- 因急性心肌梗死导致院外心脏骤停后心源性休克、经复苏的患者,2014年9月至2016年9月单中心连续纳入,共90例。
- Impella组27例,药物治疗组63例。
研究设计与关键结果
- 回顾性单中心研究,90例AMI合并院外心脏骤停后心源性休克患者,Impella组27例 vs 药物治疗组63例。
- Impella组低流量时间29.54±10.21 vs 17.57±8.3 min(p<0.001),入院乳酸4.75 [IQR 3.8-11] vs 3.6 [IQR 2.6-3.9] mmol/L(p=0.03),基线收缩期左室射血分数25% [IQR 25-35] vs 45% [IQR 35-51.25](p<0.001)。
- 倾向评分匹配后,Impella组出院生存率65% vs 药物治疗组20%(p=0.01),6个月生存率60% vs 20%(p=0.02)。
证据类型、等级与局限
- 证据类型:回顾性单中心研究,采用倾向评分匹配分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在因AMI导致院外心脏骤停后心源性休克的患者中,Impella支持与药物治疗相比与更好的出院生存率和6个月生存率相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: To compare survival outcomes of Impella support and medical treatment in patients with post-cardiac arrest cardiogenic shock related to acute myocardial infarction (AMI).
METHODS: Retrospective single center study of patients resuscitated from out of hospital cardiac arrest (OHCA) due to AMI with post-cardiac arrest cardiogenic shock between September 2014 and September 2016. Patients were either assisted with Impella or received medical treatment only. Survival outcomes were compared using propensity score-matched analysis to account for differences in baseline characteristics between both groups.
RESULTS: A total of 90 consecutive patients with post-cardiac arrest shock due to AMI were included; 27 patients in the Impella group and 63 patients in the medical treatment group. Patients with Impella support had a longer duration of low-flow time (29.54 ± 10.21 versus 17.57 ± 8.3 min, p < 0.001), higher lactate levels on admission (4.75 [IQR 3.8-11] versus 3.6 [IQR 2.6-3.9] mmol/L, p = 0.03) and lower baseline systolic LVEF (25% [IQR 25-35] versus 45% [IQR 35-51.25], p < 0.001) as compared to patients without circulatory support. After propensity score matching, patients with Impella support had a significantly higher survival to hospital discharge (65% versus 20%, p = 0.01) and 6-months survival (60% versus 20%, p = 0.02).
CONCLUSION: The results from our study suggest that Impella support is associated with significantly better survival to hospital discharge and at 6 months compared to medical treatment in OHCA patients admitted with post-cardiac arrest cardiogenic shock and AMI.
参考来源
- Karatolios K, Chatzis G, Markus B, et al. Impella support compared to medical treatment for post-cardiac arrest shock after out of hospital cardiac arrest. Resuscitation. 2018. PMID: 29522829. doi:10.1016/j.resuscitation.2018.03.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。